Atrium Therapeutics, Inc. (RNA) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 7 Buy, 9 Hold.
The consensus price target is $54.50 (low: $50.00, high: $59.00), representing an upside of 288.7% from the current price $14.02.
Analysts estimate Earnings Per Share (EPS) of $-2.87 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.89 vs est $-2.87 (missed -0.7%). 2025: actual $-4.48 vs est $-4.57 (beat +1.9%). Analyst accuracy: 99%.
RNA Stock — 12-Month Price Forecast
$54.50
▲ +288.73% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Atrium Therapeutics, Inc., the average price target is $54.50, with a high forecast of $59.00, and a low forecast of $50.00.
The average price target represents a +288.73% change from the last price of $14.02.
Highest Price Target
$59.00
Average Price Target
$54.50
Lowest Price Target
$50.00
RNA Analyst Ratings
Hold
Based on 16 analysts giving stock ratings to Atrium Therapeutics, Inc. in the past 3 months
EPS Estimates — RNA
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.89
vs Est –$2.87
▼ 0.7% off
2025
Actual –$4.48
vs Est –$4.57
▲ 2.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — RNA
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.011B
vs Est $0.010B
▲ 10.6% off
2025
Actual $0.019B
vs Est $0.021B
▼ 13.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
